BioSpace News Archive

Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, has formed a Scientific Advisory Board (SAB).

Biodexa Pharmaceuticals PLC announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

Ashvattha Therapeutics announced the presentation of data demonstrating the therapeutic potential of Ashvattha’s novel CSF1R dendranib for MS based on symptom reduction in a mouse experimental autoimmune encephalitis model.

Surrozen, Inc. presented a poster on the preliminary results of a Phase 1a study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis on June 8, 2024 at the 2024 European Association for the Study of the Liver in Milan.

RenovoRx, Inc. announced that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.

GeneDx, a leader in delivering improved health outcomes through genomic insights, announced that it is expanding access to its rapid whole genome sequencing services in neonatal intensive care units with leading health systems through a new collaboration with Epic.

SeaStar Medical Holding Corporation announces that three new members have joined its Board of Directors.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Company posted a new Shareholder Update Letter on its website NRx Shareholder Update and further invites interested parties to subscribe to their email alert service to stay up to date on company’s progress here: NRx Email Alerts..

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced positive preclinical study results highlighting the potential efficacy and safety profile of Ketamir-2, MIRA’s novel oral ketamine analog designed to treat depression and treatment-resistant depression (TRD).